Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Axcess Global Sciences LLC currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct art units, indicating that each action is being evaluated by a different specialized group. The 4 pending office actions represent the total current volume for the company in this sector.
The prosecution involves 4 distinct examiners, ensuring that no two actions are reviewed by the same individual. HOWELL, THEODORE R is the busiest examiner, currently overseeing 1 busiest examiner pending actions. This 1 busiest examiner pending actions is the same volume as the other pending matters in the portfolio.
Because the 4 distinct examiners are handling the 4 pending office actions, there is no concentration of workload under a single person. The 4 distinct art units involved suggest that the company must navigate different procedural requirements for each application. HOWELL, THEODORE R and the other examiners provide a decentralized review process within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
| MCMILLIAN, KARA RENITA | 1 | 30.9% | +37.9% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926122 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | RAMACHANDRAN, UMAMAHESWARI | 11d overdue |
| 16551594 | COMPOSITIONS AND METHODS FOR DELIVERING TETRAHYDROCANNABINOL AND KETONE BODIES | NEAGU, IRINA | 63d |
| 19303084 | SOLID R-BETA-HYDROXYBUTYRIC ACID COMPOSITION | MCMILLIAN, KARA RENITA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926122 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | RAMACHANDRAN, UMAMAHESWARI | 11d overdue |
| 16551594 | COMPOSITIONS AND METHODS FOR DELIVERING TETRAHYDROCANNABINOL AND KETONE BODIES | NEAGU, IRINA | 63d |
| 19319520 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS TO IMPROVE HEART FUNCTION IN A HUMAN | HOWELL, THEODORE R | — |
| 19303084 | SOLID R-BETA-HYDROXYBUTYRIC ACID COMPOSITION | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19319520 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS TO IMPROVE HEART FUNCTION IN A HUMAN | HOWELL, THEODORE R | 1628 | §112DP | Non-Final OA | — | Pending | Sep 04, 2025 |
| 19303084 | SOLID R-BETA-HYDROXYBUTYRIC ACID COMPOSITION | MCMILLIAN, KARA RENITA | 1623 | §102§103Other | Non-Final OA | — | Pending | Aug 18, 2025 |
| 18926122 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103§112 | Final Rejection | 11d overdue | Pending | Oct 24, 2024 |
| 16551594 | COMPOSITIONS AND METHODS FOR DELIVERING TETRAHYDROCANNABINOL AND KETONE BODIES | NEAGU, IRINA | 1629 | §103§112 | Final Rejection | 63d | Pending | Aug 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxcess Global Sciences LLC has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Theodore R Howell has the most, with 1 of Axcess Global Sciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
